<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617523</url>
  </required_header>
  <id_info>
    <org_study_id>GRC90</org_study_id>
    <secondary_id>U1111-1211-4864</secondary_id>
    <nct_id>NCT03617523</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations</brief_title>
  <acronym>GRC90</acronym>
  <official_title>Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study were:

        -  To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent
           vaccine in children 6 to less than (&lt;) 36 months of age and 3 to &lt;9 years of age, and in
           adults 18 to &lt;65 years of age; the immunogenicity of the 2018-2019 formulation of
           Flublok® Quadrivalent vaccine in adults 18 to &lt;65 years of age; and the immunogenicity
           of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults greater than or
           equal to (&gt;=) 65 years of age.

        -  To describe the safety of the 2018-2019 formulation of Fluzone Quadrivalent vaccine in
           children 6 to &lt;36 months of age and 3 to &lt;9 years of age, and in adults 18 to &lt;65 years
           of age; the safety of the 2018-2019 formulation of Flublok Quadrivalent vaccine in
           adults 18 to &lt;65 years of age; and the safety of the 2018-2019 formulation of Fluzone
           High-Dose vaccine in adults &gt;=65 years of age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant was approximately 21 days for adult participants or 28 days
      for child participants who received one dose of vaccine, and 56 days for participants who
      received two doses of vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">November 12, 2018</completion_date>
  <primary_completion_date type="Actual">November 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was partially randomized. Participants were assigned a vaccine group based on age. Participants in Groups 1, 2, and 5 were not randomly assigned, while participants in Groups 3 and 4 were randomly assigned.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants (Group 1: Aged 6 to &lt;36 Months) Reporting Solicited Injection Site Reactions and Systemic Reactions</measure>
    <time_frame>Within 7 days post any vaccination</time_frame>
    <description>A solicited reaction was an adverse event (AE) that was pre-listed in the electronic case report form (eCRF) and considered to be related to vaccination. Solicited injection (Inj.) site reactions: tenderness, erythema and swelling. Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost and irritability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants (Groups 2, 3, 4 and 5: Children Aged 3 to &lt;9 Years and Adults 18 to &gt;=65 Years) Reporting Solicited Injection Site Reactions or Systemic Reactions</measure>
    <time_frame>Within 7 days post any vaccination</time_frame>
    <description>A solicited reaction was an AE that was pre-listed in the eCRF and considered to be related to vaccination. Solicited injection site reactions: pain, erythema and swelling. Solicited systemic reactions: fever, headache, malaise, and myalgia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</measure>
    <time_frame>28 days post-final vaccination</time_frame>
    <description>GMT of anti-influenza antibodies were measured using a hemagglutination inhibition (HAI) assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</measure>
    <time_frame>Day 21 (post-vaccination)</time_frame>
    <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratios (GMTRs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination), 28 days post-final vaccination</time_frame>
    <description>GMT of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-final vaccination and pre-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratios of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination), Day 21 (post-vaccination)</time_frame>
    <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Groups 1 and 2</measure>
    <time_frame>28 days post-final vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroprotection was defined as antibody titer &gt;=40 (1/ dilution) at pre-vaccination and at post-final vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</measure>
    <time_frame>Day 21 (post-vaccination)</time_frame>
    <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. Seroprotection was defined as antibody titer &gt;=40 (1/dilution) at pre-vaccination and at post-final vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Group 1 and 2</measure>
    <time_frame>28 days post-final vaccination</time_frame>
    <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-final vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-final vaccination titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</measure>
    <time_frame>Day 21 (post-vaccination)</time_frame>
    <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Group 3 and 4, and using an HAI assay for 3 strains: A/H1N1, A/H3N2, and B Victoria lineage in Group 5. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-vaccination titer.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 1: 6 to &lt;36 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (aged 6 to &lt;36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 2: 3 to &lt;9 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 3: 18 to &lt;65 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flublok Quadrivalent vaccine Group 4: 18 to &lt;65 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluzone High-Dose vaccine Group 5: &gt;=65 years</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone Quadrivalent vaccine, 2018-2019 formulation</intervention_name>
    <description>Pharmaceutical form: Suspension for injection Route of administration: Intramuscular</description>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 1: 6 to &lt;36 months</arm_group_label>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 2: 3 to &lt;9 years</arm_group_label>
    <arm_group_label>Fluzone Quadrivalent vaccine Group 3: 18 to &lt;65 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublok Quadrivalent vaccine, 2018-2019 formulation</intervention_name>
    <description>Pharmaceutical form: Suspension for injection Route of administration: Intramuscular</description>
    <arm_group_label>Flublok Quadrivalent vaccine Group 4: 18 to &lt;65 years</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone High-Dose vaccine, 2018-2019 formulation</intervention_name>
    <description>Pharmaceutical form: Suspension for injection Route of administration: Intramuscular</description>
    <arm_group_label>Fluzone High-Dose vaccine Group 5: &gt;=65 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Aged 6 months to &lt;9 years or &gt;=18 years on the day of first study vaccination (study
             product administration).

          -  For participants 6 to &lt;12 months of age, born at full term of pregnancy (&gt;=37 weeks)
             and with a birth weight &gt;=2.5 kilograms (kg) (5.5 pounds [lbs.]).

          -  Informed consent form (ICF) had been signed and dated by participants &gt;=18 years of
             age.

          -  Assent form had been signed and dated by participants 7 to &lt;9 years of age, and ICF
             had been signed and dated by parent(s) or guardian(s) for participants 6 months to &lt;9
             years of age.

          -  Participants and parent/guardian (of participants 6 months to &lt;9 years of age) were
             able to attend all scheduled visits and to comply with all study procedures.

        Exclusion criteria:

          -  Participant was pregnant, or lactating, or of childbearing potential and not using an
             effective method of contraception or abstinence from at least 4 weeks prior to
             vaccination and until at least 4 weeks after vaccination. To be considered of
             non-childbearing potential, a female must be pre-menarche, or post-menopausal for at
             least 1 year, or surgically sterile.

          -  Participation at the time of study enrollment (or in the 30 days preceding the first
             study vaccination) or planned participation during the present study period in another
             clinical study investigating a vaccine, drug, medical device, or medical procedure.

          -  Receipt of any vaccine in the 30 days preceding the first study vaccination, or
             planned receipt of any vaccine before Visit 2 for participants who received 1 dose of
             influenza vaccine or Visit 3 for participants who received 2 doses of influenza
             vaccine.

          -  Previous vaccination against influenza (in the 2018-2019 influenza season) with either
             study vaccine or another vaccine.

          -  Receipt of immune globulins, blood, or blood-derived products in the 3 months
             preceding planned inclusion.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the 6 months preceding planned inclusion; or long-term systemic corticosteroid
             therapy (prednisone or equivalent for more than 2 consecutive weeks within the 3
             months preceding planned inclusion).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life- threatening reaction to study vaccine or to a vaccine containing any of the same
             substances.

          -  Thrombocytopenia, which might be a contraindication for intramuscular vaccination, at
             the discretion of the Investigator.

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily.

          -  Current alcohol abuse or drug addiction.

          -  Chronic illness that, in the opinion of the Investigator, was at a stage where it
             might interfere with study conduct or completion.

          -  Moderate or severe acute illness/infection (according to Investigator judgment) on the
             day of planned vaccination or febrile illness (temperature &gt;=100.4 degree Fahrenheit
             [38.0 degree Celsius]). A prospective participant was not included in the study until
             the condition had resolved or the febrile event had subsided.

          -  Identified as an Investigator or employee of the Investigator or study center with
             direct involvement in the proposed study (participants &gt;=18 years of age) or
             identified as an immediate family member (i.e., parent, spouse, natural or adopted
             child) of the Investigator or employee with direct involvement in the proposed study
             (all participants).

          -  History of serious adverse reaction to any influenza vaccine.

          -  Personal history of Guillain-Barré syndrome.

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             participant if enrolled or could interfere with the evaluation of the vaccine.

          -  Personal history of clinically significant developmental delay (at the discretion of
             the Investigator), neurologic disorder, or seizure disorder.

          -  Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <results_first_submitted>November 5, 2019</results_first_submitted>
  <results_first_submitted_qc>November 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 25, 2019</results_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to participant-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Participant level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03617523/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03617523/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 10 September 2018 to 22 October 2018 at 3 centers in the United States.</recruitment_details>
      <pre_assignment_details>A total of 240 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
          <description>Participants (aged 6 to less than [&lt;] 36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P2">
          <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
          <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P3">
          <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="P4">
          <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="P5">
          <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
          <description>Participants (aged greater than or equal to [&gt;=] 65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on safety analysis set which included participants who received at least 1 dose of study vaccine.</population>
      <group_list>
        <group group_id="B1">
          <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
          <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B2">
          <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
          <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B3">
          <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="B4">
          <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
          <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="59"/>
            <count group_id="B5" value="60"/>
            <count group_id="B6" value="240"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.7" spread="0.44"/>
                    <measurement group_id="B2" value="5.9" spread="1.76"/>
                    <measurement group_id="B3" value="46.7" spread="13.48"/>
                    <measurement group_id="B4" value="46.2" spread="13.44"/>
                    <measurement group_id="B5" value="73.6" spread="6.42"/>
                    <measurement group_id="B6" value="42.6" spread="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants (Group 1: Aged 6 to &lt;36 Months) Reporting Solicited Injection Site Reactions and Systemic Reactions</title>
        <description>A solicited reaction was an adverse event (AE) that was pre-listed in the electronic case report form (eCRF) and considered to be related to vaccination. Solicited injection (Inj.) site reactions: tenderness, erythema and swelling. Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost and irritability.</description>
        <time_frame>Within 7 days post any vaccination</time_frame>
        <population>Analysis was performed on safety analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
            <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Group 1: Aged 6 to &lt;36 Months) Reporting Solicited Injection Site Reactions and Systemic Reactions</title>
          <description>A solicited reaction was an adverse event (AE) that was pre-listed in the electronic case report form (eCRF) and considered to be related to vaccination. Solicited injection (Inj.) site reactions: tenderness, erythema and swelling. Solicited systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost and irritability.</description>
          <population>Analysis was performed on safety analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants (Groups 2, 3, 4 and 5: Children Aged 3 to &lt;9 Years and Adults 18 to &gt;=65 Years) Reporting Solicited Injection Site Reactions or Systemic Reactions</title>
        <description>A solicited reaction was an AE that was pre-listed in the eCRF and considered to be related to vaccination. Solicited injection site reactions: pain, erythema and swelling. Solicited systemic reactions: fever, headache, malaise, and myalgia.</description>
        <time_frame>Within 7 days post any vaccination</time_frame>
        <population>Analysis was performed on safety analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
            <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
            <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants (Groups 2, 3, 4 and 5: Children Aged 3 to &lt;9 Years and Adults 18 to &gt;=65 Years) Reporting Solicited Injection Site Reactions or Systemic Reactions</title>
          <description>A solicited reaction was an AE that was pre-listed in the eCRF and considered to be related to vaccination. Solicited injection site reactions: pain, erythema and swelling. Solicited systemic reactions: fever, headache, malaise, and myalgia.</description>
          <population>Analysis was performed on safety analysis set.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</title>
        <description>GMT of anti-influenza antibodies were measured using a hemagglutination inhibition (HAI) assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage.</description>
        <time_frame>28 days post-final vaccination</time_frame>
        <population>Analysis was performed on per-protocol analysis set which included participants who received at least 1 dose of the study vaccine and had a valid post-vaccination blood sample result for at least 1 strain without any protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
            <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
            <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</title>
          <description>GMT of anti-influenza antibodies were measured using a hemagglutination inhibition (HAI) assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage.</description>
          <population>Analysis was performed on per-protocol analysis set which included participants who received at least 1 dose of the study vaccine and had a valid post-vaccination blood sample result for at least 1 strain without any protocol deviations.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="108" upper_limit="487"/>
                    <measurement group_id="O2" value="1008" lower_limit="605" upper_limit="1680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="94.0" upper_limit="606"/>
                    <measurement group_id="O2" value="1109" lower_limit="671" upper_limit="1833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160" lower_limit="79.3" upper_limit="323"/>
                    <measurement group_id="O2" value="688" lower_limit="390" upper_limit="1211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295" lower_limit="167" upper_limit="524"/>
                    <measurement group_id="O2" value="1343" lower_limit="811" upper_limit="2223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</title>
        <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5.</description>
        <time_frame>Day 21 (post-vaccination)</time_frame>
        <population>Analysis was performed on per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
            <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</title>
          <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5.</description>
          <population>Analysis was performed on per-protocol analysis set.</population>
          <units>titers (1/dilutions)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525" lower_limit="386" upper_limit="712"/>
                    <measurement group_id="O2" value="708" lower_limit="498" upper_limit="1007"/>
                    <measurement group_id="O3" value="266" lower_limit="195" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379" lower_limit="276" upper_limit="523"/>
                    <measurement group_id="O2" value="644" lower_limit="456" upper_limit="909"/>
                    <measurement group_id="O3" value="359" lower_limit="255" upper_limit="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="588" lower_limit="447" upper_limit="773"/>
                    <measurement group_id="O2" value="525" lower_limit="388" upper_limit="711"/>
                    <measurement group_id="O3" value="453" lower_limit="337" upper_limit="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759" lower_limit="571" upper_limit="1009"/>
                    <measurement group_id="O2" value="1102" lower_limit="829" upper_limit="1465"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data not reported since the immune response to the B Yamagata lineage strain was not assessed in Group 5 participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratios (GMTRs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</title>
        <description>GMT of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-final vaccination and pre-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination), 28 days post-final vaccination</time_frame>
        <population>Analysis was performed on per-protocol analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
            <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
            <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios (GMTRs) of Antibodies in Children 6 Months to &lt;9 Years of Age (Groups 1 and 2) Receiving Fluzone Quadrivalent Vaccine</title>
          <description>GMT of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-final vaccination and pre-vaccination.</description>
          <population>Analysis was performed on per-protocol analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1(post-final vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" lower_limit="5.38" upper_limit="15.3"/>
                    <measurement group_id="O2" value="4.47" lower_limit="2.39" upper_limit="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2(post-final vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" lower_limit="1.92" upper_limit="8.12"/>
                    <measurement group_id="O2" value="6.40" lower_limit="3.95" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria(post-final vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.11" lower_limit="4.84" upper_limit="13.6"/>
                    <measurement group_id="O2" value="13.3" lower_limit="8.61" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata(post-final vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="7.24" upper_limit="19.2"/>
                    <measurement group_id="O2" value="8.41" lower_limit="4.98" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratios of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</title>
        <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination), Day 21 (post-vaccination)</time_frame>
        <population>Analysis was performed on per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
            <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios of Antibodies in Adults (Groups 3, 4 and 5) Receiving Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine, or Fluzone High-Dose Vaccine</title>
          <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
          <population>Analysis was performed on per-protocol analysis set.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (post-vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="2.02" upper_limit="4.23"/>
                    <measurement group_id="O2" value="6.34" lower_limit="4.17" upper_limit="9.63"/>
                    <measurement group_id="O3" value="3.07" lower_limit="2.34" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (post-vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" lower_limit="2.60" upper_limit="4.85"/>
                    <measurement group_id="O2" value="8.19" lower_limit="5.56" upper_limit="12.1"/>
                    <measurement group_id="O3" value="3.69" lower_limit="2.68" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria (post-vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="2.43" upper_limit="4.73"/>
                    <measurement group_id="O2" value="4.40" lower_limit="3.13" upper_limit="6.19"/>
                    <measurement group_id="O3" value="3.65" lower_limit="2.79" upper_limit="4.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata (post-vaccination/pre-vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.10" upper_limit="3.85"/>
                    <measurement group_id="O2" value="5.20" lower_limit="3.76" upper_limit="7.21"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data not reported since the immune response to the B Yamagata lineage strain was not assessed in Group 5 participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Groups 1 and 2</title>
        <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroprotection was defined as antibody titer &gt;=40 (1/ dilution) at pre-vaccination and at post-final vaccination.</description>
        <time_frame>28 days post-final vaccination</time_frame>
        <population>Analysis was performed on per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
            <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
            <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Groups 1 and 2</title>
          <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroprotection was defined as antibody titer &gt;=40 (1/ dilution) at pre-vaccination and at post-final vaccination.</description>
          <population>Analysis was performed on per-protocol analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" lower_limit="65.1" upper_limit="95.6"/>
                    <measurement group_id="O2" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="60.6" upper_limit="93.4"/>
                    <measurement group_id="O2" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="60.6" upper_limit="93.4"/>
                    <measurement group_id="O2" value="100" lower_limit="88.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                    <measurement group_id="O2" value="96.6" lower_limit="82.2" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</title>
        <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. Seroprotection was defined as antibody titer &gt;=40 (1/dilution) at pre-vaccination and at post-final vaccination.</description>
        <time_frame>Day 21 (post-vaccination)</time_frame>
        <population>Analysis was performed on per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
            <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</title>
          <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Groups 3 and 4, and using HAI assay for 3 strains: A/H1N1, A/H3N2 and B Victoria lineage in Group 5. Seroprotection was defined as antibody titer &gt;=40 (1/dilution) at pre-vaccination and at post-final vaccination.</description>
          <population>Analysis was performed on per-protocol analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="93.3" lower_limit="83.8" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="91.2" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="98.3" lower_limit="91.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.1" upper_limit="100"/>
                    <measurement group_id="O2" value="98.3" lower_limit="90.8" upper_limit="100"/>
                    <measurement group_id="O3" value="98.3" lower_limit="91.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data not reported since the immune response to the B Yamagata lineage strain was not assessed in Group 5 participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Group 1 and 2</title>
        <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-final vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-final vaccination titer.</description>
        <time_frame>28 days post-final vaccination</time_frame>
        <population>Analysis was performed on per-protocol analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
            <description>Participants (aged 6 to &lt;36 months) received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
            <description>Participants (aged 3 to &lt;9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Fluzone Quadrivalent Vaccine: Group 1 and 2</title>
          <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-final vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-final vaccination titer.</description>
          <population>Analysis was performed on per-protocol analysis set. Here, ‘Overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                    <measurement group_id="O2" value="42.9" lower_limit="24.5" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="34.9" upper_limit="75.6"/>
                    <measurement group_id="O2" value="64.3" lower_limit="44.1" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="59.3" upper_limit="93.2"/>
                    <measurement group_id="O2" value="92.9" lower_limit="76.5" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O2" value="78.6" lower_limit="59.0" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</title>
        <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Group 3 and 4, and using an HAI assay for 3 strains: A/H1N1, A/H3N2, and B Victoria lineage in Group 5. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-vaccination titer.</description>
        <time_frame>Day 21 (post-vaccination)</time_frame>
        <population>Analysis was performed on per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O2">
            <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
            <description>Participants (aged 18 to &lt;65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
          </group>
          <group group_id="O3">
            <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
            <description>Participants (aged &gt;=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With Either Fluzone Quadrivalent Vaccine, Flublok Quadrivalent Vaccine or Fluzone High Dose Vaccine: Group 3, 4 and 5</title>
          <description>Anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage in Group 3 and 4, and using an HAI assay for 3 strains: A/H1N1, A/H3N2, and B Victoria lineage in Group 5. Seroconversion was defined as either a pre-vaccination titer &lt;10 (1/dilution) and a post-vaccination titer &gt;= 40 (1/dilution) or a pre-vaccination titer &gt;= 10 (1/dilution) and &gt;=4-fold increase in post-vaccination titer.</description>
          <population>Analysis was performed on per-protocol analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="58"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.3" upper_limit="46.0"/>
                    <measurement group_id="O2" value="51.7" lower_limit="38.2" upper_limit="65.0"/>
                    <measurement group_id="O3" value="46.7" lower_limit="33.7" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" lower_limit="31.5" upper_limit="57.6"/>
                    <measurement group_id="O2" value="70.7" lower_limit="57.3" upper_limit="81.9"/>
                    <measurement group_id="O3" value="50.0" lower_limit="36.8" upper_limit="63.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8" lower_limit="21.3" upper_limit="46.0"/>
                    <measurement group_id="O2" value="46.6" lower_limit="33.3" upper_limit="60.1"/>
                    <measurement group_id="O3" value="46.7" lower_limit="33.7" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="17.1" upper_limit="40.8"/>
                    <measurement group_id="O2" value="55.2" lower_limit="41.5" upper_limit="68.3"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Data not reported since the immune response to the B Yamagata lineage strain was not assessed in Group 5 participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day 0 (post-vaccination) up to study end ( i.e., up to Day 21 for adult participants or Day 28 for child participants who received 1 dose; up to Day 56 for participants who received 2 doses).</time_frame>
      <desc>Solicited reaction (SR) is an AE prelisted in eCRF and considered related to vaccination. A SR is, therefore, an adverse drug reaction observed and reported under conditions prelisted (solicited) in eCRF. An Unsolicited AE is an observed AE that does not fulfill conditions prelisted in eCRF in terms of symptom and/or time to onset post-vaccination. Non-serious adverse events (non-SAE) included SR (within 7 days after vaccination) and unsolicited non-SAE (within 28 days after final vaccination)</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluzone Quadrivalent Vaccine Group 1: 6 to &lt;36 Months</title>
          <description>Participants (aged 6 to &lt;36 months) received a 0.25 mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E2">
          <title>Fluzone Quadrivalent Vaccine Group 2: 3 to &lt;9 Years</title>
          <description>Participants (aged 3 to &lt;9 years) received a 0.5 mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E3">
          <title>Fluzone Quadrivalent Vaccine Group 3: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5 mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="E4">
          <title>Flublok Quadrivalent Vaccine Group 4: 18 to &lt;65 Years</title>
          <description>Participants (aged 18 to &lt;65 years) received a 0.5 mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.</description>
        </group>
        <group group_id="E5">
          <title>Fluzone High-Dose Vaccine Group 5: &gt;=65 Years</title>
          <description>Participants (aged &gt;=65 years) received a 0.5 mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="61"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="59"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="61"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="59"/>
                <counts group_id="E5" events="24" subjects_affected="24" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="61"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="61"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="61"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="59"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

